Document Detail


Antihypertensive treatment and serum cholesterol: results of population-based surveys in the German Cardiovascular Prevention Study.
MedLine Citation:
PMID:  9553999     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We analyzed the data from three cross-sectional, population-based surveys in West Germany to evaluate the effect of antihypertensive drug therapy on the level of serum cholesterol in German residents (18,344 males; 19,137 females) aged 25-69 years, after excluding persons with missing values (N = 5529) for any study variable. The data were obtained from the national and regional health surveys that were conducted during the years 1984-1992, within the framework of the German Cardiovascular Prevention Study (GCP). The response rates were between 66.0% and 71.4% for the national surveys and between 65.9% and 83.3% for the regional surveys. Blood-pressure and non-fasting cholesterol measurements were carried out under strictly standardized conditions. Multiple linear regression analysis was used to compare the age-adjusted mean value and prevalence for each of the following study variables: total serum cholesterol, HDL-cholesterol, non-HDL cholesterol, and the ratio of HDL cholesterol/total cholesterol for users and non-users of antihypertensive medications. Antihypertensive medications were reportedly taken during the seven days preceding the survey examination by 7.8% of all males and 10.4% of all females. The beta-blocker type of medication was prescribed most frequently for lowering high blood pressure. In both genders, the strongest age-adjusted effect of an increase in cholesterol level was found for beta-blockers. The difference in the age-adjusted means for non-HDL cholesterol values between users and non-users of beta-blockers was 9.2 mg/dL (p < 0.001) in males and 9.0 mg/dL (p < 0.001) in females. Regression analysis carried out to control for several potential confounders confirmed the results. The findings suggest that mass treatment of hypertension with beta-blockers may be associated with reductions in benefit because of an increase in non-HDL and a decrease in HDL cholesterol levels.
Authors:
U Helmert; S Shea
Related Documents :
2337149 - Urea gradient-associated fluid absorption with sigma urea = 1 in rat terminal collectin...
2112619 - Effects of nonglucose substrates (xylitol, medium-chain triglycerides, long-chain trigl...
9482759 - Dietary iron intake rapidly influences iron regulatory proteins, ferritin subunits and ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Reviews on environmental health     Volume:  12     ISSN:  0048-7554     ISO Abbreviation:  Rev Environ Health     Publication Date:    1997 Oct-Dec
Date Detail:
Created Date:  1998-05-29     Completed Date:  1998-05-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0425754     Medline TA:  Rev Environ Health     Country:  ISRAEL    
Other Details:
Languages:  eng     Pagination:  253-60     Citation Subset:  IM    
Affiliation:
Department for Health Policy, Occupational and Social Medicine, Bremen University, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / pharmacology,  therapeutic use
Adult
Aged
Antihypertensive Agents / pharmacology*,  therapeutic use
Cardiovascular Diseases / prevention & control
Cholesterol / analysis,  blood*
Cholesterol, HDL / analysis,  blood
Cross-Sectional Studies
Female
Germany
Health Surveys
Humans
Hypertension / drug therapy*
Male
Middle Aged
Regression Analysis
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Cholesterol, HDL; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The toxicologic hazard of superfund hazardous-waste sites.
Next Document:  Mastocytosis: magnetic resonance imaging patterns of marrow disease.